4.81
Aldeyra Therapeutics Inc stock is traded at $4.81, with a volume of 1.51M.
It is down -3.61% in the last 24 hours and up +22.39% over the past month.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
See More
Previous Close:
$4.99
Open:
$4.9
24h Volume:
1.51M
Relative Volume:
1.35
Market Cap:
$288.10M
Revenue:
-
Net Income/Loss:
$-44.80M
P/E Ratio:
-6.4133
EPS:
-0.75
Net Cash Flow:
$-30.67M
1W Performance:
-6.96%
1M Performance:
+22.39%
6M Performance:
-8.21%
1Y Performance:
+29.65%
Aldeyra Therapeutics Inc Stock (ALDX) Company Profile
Name
Aldeyra Therapeutics Inc
Sector
Industry
Phone
781-761-4904
Address
131 HARTWELL AVENUE, LEXINGTON, MA
Compare ALDX with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
ALDX
Aldeyra Therapeutics Inc
|
4.81 | 298.88M | 0 | -44.80M | -30.67M | -0.75 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Aldeyra Therapeutics Inc Stock (ALDX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Apr-03-24 | Upgrade | Oppenheimer | Perform → Outperform |
Apr-02-24 | Resumed | H.C. Wainwright | Buy |
Apr-27-22 | Resumed | H.C. Wainwright | Buy |
Feb-08-21 | Initiated | H.C. Wainwright | Buy |
Dec-16-20 | Initiated | Berenberg | Buy |
Oct-30-20 | Initiated | Jefferies | Buy |
Oct-16-20 | Initiated | BTIG Research | Buy |
Sep-22-20 | Initiated | Alliance Global Partners | Buy |
May-12-20 | Initiated | Oppenheimer | Outperform |
Dec-04-18 | Initiated | Citigroup | Buy |
Sep-26-18 | Reiterated | Cantor Fitzgerald | Overweight |
Sep-13-18 | Initiated | Janney | Buy |
Jan-26-18 | Initiated | Seaport Global Securities | Buy |
Sep-26-16 | Initiated | H.C. Wainwright | Buy |
Jul-01-16 | Initiated | Stifel | Buy |
Jul-01-15 | Initiated | Canaccord Genuity | Buy |
Mar-25-15 | Initiated | Chardan Capital Markets | Buy |
Mar-20-15 | Reiterated | H.C. Wainwright | Buy |
Nov-18-14 | Initiated | H.C. Wainwright | Buy |
Jun-19-14 | Initiated | Aegis Capital | Buy |
View All
Aldeyra Therapeutics Inc Stock (ALDX) Latest News
Is Aldeyra Therapeutics Inc. stock overvalued or undervaluedEarnings Report Alerts With Proven Results - jammulinksnews.com
When is Aldeyra Therapeutics Inc. stock expected to show significant growthAdvanced Screener Growth Plan For Every Investor - jammulinksnews.com
What makes Aldeyra Therapeutics Inc. stock price move sharplyTop Growth Insights For Consistent Profits - jammulinksnews.com
What are analysts’ price targets for Aldeyra Therapeutics Inc. in the next 12 monthsWealth Building Insights That Work - jammulinksnews.com
Exploring US High Growth Tech Stocks For July 2025 - simplywall.st
Should I hold or sell Aldeyra Therapeutics Inc. stock in 2025Expert Picks Report For Fast Growth - jammulinksnews.com
How many analysts rate Aldeyra Therapeutics Inc. as a “Buy”Beginner Investor Data Feed For Every Investor - jammulinksnews.com
Why Aldeyra Therapeutics Inc. stock attracts strong analyst attentionConsistent Gain Investment Strategies Emerge - metal.it
Published on: 2025-07-29 20:51:08 - metal.it
Trendline Breach Raises Concern for Aldeyra Therapeutics Inc. InvestorsCommunity Verified Stock Suggestions Drive Volume - metal.it
Why did ALDX's EPS remain stagnant in recent quarters? - AInvest
How does Aldeyra Therapeutics Inc. generate profit in a changing economyMarket Forecast Target Finder For 2025 - jammulinksnews.com
How Aldeyra Therapeutics Inc. stock performs during market volatilityFundamental Growth Stock Analysis Shows Strength - metal.it
How volatile is Aldeyra Therapeutics Inc. stock compared to the marketUnmatched market performance - jammulinksnews.com
Why is Aldeyra Therapeutics Inc. stock attracting strong analyst attentionDiscover stocks with explosive upside potential - jammulinksnews.com
What makes Aldeyra Therapeutics Inc. stock attractive to long term investorsAnalyst Grade Signals - metal.it
What is the risk reward ratio of investing in Aldeyra Therapeutics Inc. stockCapitalize on strategic market trends - jammulinksnews.com
What are Aldeyra Therapeutics Inc. company’s key revenue driversUnlock high-yield investment opportunities - jammulinksnews.com
Aldeyra Therapeutics receives orphan designation for ADX-2191 from EMA - Ophthalmology Times
Is Aldeyra Therapeutics Inc. a good long term investmentExplosive earning power - PrintWeekIndia
Aldeyra Therapeutics Receives Orphan Designation from the Europe - GuruFocus
What drives Aldeyra Therapeutics Inc. stock priceFree Risk Assessment Services - PrintWeekIndia
What analysts say about Aldeyra Therapeutics Inc. stockExceptional gains - Autocar Professional
EMA grants orphan designation to ADX-2191 (Aldeyra Therapeutics) for inherited retinal dystrophies - Ophthalmology Times Europe
EMA grants orphan designation for Aldeyra’s eye treatment By Investing.com - Investing.com India
EMA grants orphan designation for Aldeyra’s eye treatment - Investing.com
Breakthrough: Aldeyra's Eye Drug Gets EU Orphan Status for Treating Incurable Genetic Blindness - Stock Titan
Published on: 2025-07-23 18:29:07 - Autocar Professional
Aldeyra Therapeutics Inc. Stock Analysis and ForecastSuperior returns - jammulinksnews.com
ALDX Up as FDA Accepts Resubmitted NDA for Eye Drug Reproxalap - MSN
FDA accepts Aldeyra's resubmitted reproxalap NDA - Eyes On Eyecare
Aldeyra Therapeutics Inc Stock (ALDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):